Adam Kern

发表

Invasive measurement of portal hypertension in the hemodynamics laboratory as an important element of qualification for the treatment of esophageal varices: A single-center experience

R. Jalali, D. Onichimowski, J. Bil, 2021 .

Complete Blood Count-Derived Indices as Prognostic Factors of 5-Year Outcomes in Patients With Confirmed Coronary Microvascular Spasm

R. Jalali, D. Onichimowski, J. Bil, 2022, Frontiers in Cardiovascular Medicine.

Platelet distribution width as the prognostic marker in coronary bifurcation treatment

R. Gil, B. Januszko-Giergielewicz, J. Bil, 2017, European journal of clinical investigation.

First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.

R. Gil, T. Pawlowski, J. Bil, 2018, Kardiologia polska.

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

T. Stompór, D. Onichimowski, J. Kiewisz, 2021, Journal of personalized medicine.

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study

J. Wójcik, G. Specchia, A. Budaj, 2021, Cardiology journal.

Non-st-elevation acute coronary syndrome due to a totally occluded coronary artery: a history of two twin brothers.

J. Bil, E. Sienkiewicz, Krystian Bojko, 2020, Wiadomosci lekarskie.

The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience.

R. Gil, R. Jalali, J. Bil, 2017, Cardiology journal.

Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis

R. Gil, T. Pawlowski, J. Bil, 2015, BMC Cardiovascular Disorders.

Patient with ST-elevation myocardial infarction, coronary artery embolism and no signs of coronary atherosclerosis in angiography

R. Gil, G. Wasilewski, J. Górny, 2015, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.

J. Wójcik, R. Gil, M. Lesiak, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.

R. Gil, J. Bil, A. Segiet, 2013, Cardiology journal.

First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.

J. Wójcik, R. Gil, M. Lesiak, 2012, Kardiologia polska.

Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS® stents for coronary bifurcation treatment: four-year results of randomized POLBOS I and POLBOS II clinical trials.

R. Gil, J. Bil, A. Segiet, 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.

P. Serruys, J. Wykrzykowska, R. Gil, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.

P. Serruys, J. Wykrzykowska, R. Gil, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.

V. Džavík, R. Gil, J. Bil, 2015, The Canadian journal of cardiology.

Coronary slow flow is not an adverse prognostic factor in MINOCA patients in the 5-year follow-up

J. Bil, R. Gil, P. Buller, 2023, Medical Research Journal.

The Comparison of Predicting Factors and Outcomes of MINOCA and STEMI Patients in the 5-Year Follow-Up

J. Bil, R. Gil, P. Buller, 2023, Journal of personalized medicine.

Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies

R. Mehran, R. Gil, J. Bil, 2020, Cardiovascular therapeutics.

Coronary microcirculation dysfunction in patients with arterial hypertension

J. Bil, M. Zaleska, O. Możeńska, 2018, Arterial Hypertension.

Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.

R. Gil, J. Bil, A. Kern, 2013, Cardiology journal.

THE ROLE OF INVASIVE AND NON-INVASIVE MEASUREMENTS OF HVPG IN DECISION MAKING IN PATIENTS WITH PORTAL HYPERTENSIONAND ESOPHAGEAL VARICES.

J. Bil, L. Gromadziński, Krystian Bojko, 2021, Wiadomosci lekarskie.

The predictive value of complete blood count-derived indices for major adverse cardiovascular events in MINOCA patients at 5-year follow-up

J. Bil, R. Gil, P. Buller, 2023, Medical Research Journal.

Prolonged mechanical CPR of a 48-year old male patient in severe hypothermia conducted in the emergency department – case report

D. Onichimowski, E. Bandurska-Stankiewicz, L. Gromadziński, 2018 .

Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent

R. Gil, A. Witkowski, M. Lesiak, 2019, Medicine.

48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent

J. Bil, R. Gil, P. Buller, 2023, Journal of personalized medicine.

Significance of S100B Protein as a Rapid Diagnostic Tool in Emergency Departments for Traumatic Brain Injury Patients

J. Bil, J. Romaszko, Izabela Godlewska, 2023, Journal of personalized medicine.

Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II

R. Gil, J. Bil, S. Dobrzycki, 2018, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

Posterior reversible encephalopathy syndrome (PRES) in the course of immunosuppressive therapy in A 45-year-old male with normal blood pressure – case study

R. Jalali, E. Bandurska-Stankiewicz, P. Olsztyn, 2018 .

Percutaneous Coronary Interventions with Sirolimus-Eluting Alex Plus Stents in Patients with or without Diabetes: 4-Year Results

J. Bil, R. Gil, Krystian Bojko, 2024, Journal of cardiovascular development and disease.